These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7981955)

  • 21. [Why are plasmatic apoB lipoproteins atherogenic? The hypothesis of response to retention].
    Hurt-Camejo E; Camejo G
    Invest Clin; 2001 May; 42 Suppl 1():43-73. PubMed ID: 11416984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atherosclerosis and plasma lipoprotein retention in the human aorta.
    Hoff HF; Heideman CL; Gaubatz JW
    Prog Biochem Pharmacol; 1977; 13():257-61. PubMed ID: 200957
    [No Abstract]   [Full Text] [Related]  

  • 23. Lipoprotein lipase in the arterial wall: linking LDL to the arterial extracellular matrix and much more.
    Pentikäinen MO; Oksjoki R; Oörni K; Kovanen PT
    Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):211-7. PubMed ID: 11834518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cause and significance of increased endothelial permeability in the development of arteriosclerosis].
    Herrmann W; Massmann J
    Z Gesamte Inn Med; 1976 Sep; 31(18):721-7. PubMed ID: 795176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.
    Shoji T; Nishizawa Y; Kawagishi T; Tanaka M; Kawasaki K; Tabata T; Inoue T; Morii H
    Atherosclerosis; 1997 Jun; 131(2):229-36. PubMed ID: 9199276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein(a), atherosclerosis and thrombosis.
    Dahlén GH
    Prog Lipid Res; 1991; 30(2-3):189-94. PubMed ID: 1840453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postprandial enrichment of remnant lipoproteins with apoC-I in healthy normolipidemic men with early asymptomatic atherosclerosis.
    Björkegren J; Silveira A; Boquist S; Tang R; Karpe F; Bond MG; de Faire U; Hamsten A
    Arterioscler Thromb Vasc Biol; 2002 Sep; 22(9):1470-4. PubMed ID: 12231568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Structural analysis of the interaction of low density lipoproteins with arterial intima cells in atherosclerosis].
    Bobryshev IuV; Kuznetsov AS
    Arkh Patol; 1989; 51(9):20-6. PubMed ID: 2596978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteoglycans, lipoproteins, and atherosclerosis.
    Srinivasan SR; Radhakrishnamurthy B; Vijayagopal P; Berenson GS
    Adv Exp Med Biol; 1991; 285():373-81. PubMed ID: 1858569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential role of oxidized lipids and lipoproteins in antioxidant defense.
    Parthasarathy S; Santanam N; Ramachandran S; Meilhac O
    Free Radic Res; 2000 Sep; 33(3):197-215. PubMed ID: 10993475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and anti-oxidants in arterial cells and blood lipoproteins.
    Aviram M
    Antioxid Redox Signal; 1999; 1(4):585-94. PubMed ID: 11233155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Desialylation decreases the resistance of apo B-containing lipoproteins to aggregation and increases their atherogenic potential.
    Mel'nichenko AA; Tertov VV; Ivanova OA; Aksenov DV; Sobenin IA; Popov EV; Kaplun VV; Suprun IV; Panasenko OM; Orekhov AN
    Bull Exp Biol Med; 2005 Jul; 140(1):51-4. PubMed ID: 16254619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arterial uptake and synthesis of low density lipoproteins.
    Hollander W; Paddock J; Colombo MA
    Prog Biochem Pharmacol; 1977; 13():123-33. PubMed ID: 200954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoprotein-matrix interactions in macrovascular disease in diabetes.
    Tannock LR; Chait A
    Front Biosci; 2004 May; 9():1728-42. PubMed ID: 14977582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system.
    Björnheden T; Babyi A; Bondjers G; Wiklund O
    Atherosclerosis; 1996 Jun; 123(1-2):43-56. PubMed ID: 8782836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modification of plasma lipoproteins by group IIA phospholipase A(2): possible implications for atherogenesis.
    Sartipy P; Hurt-Camejo E
    Trends Cardiovasc Med; 1999 Nov; 9(8):232-8. PubMed ID: 11094331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Localization of atherosclerosis in arterial junctions. Concentration distribution of low density lipoproteins at the luminal surface in regions of disturbed flow.
    Deng X; King MW; Guidoin R
    ASAIO J; 1995; 41(1):58-67. PubMed ID: 7727823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma.
    Mamo JC; Proctor SD; Smith D
    Atherosclerosis; 1998 Dec; 141 Suppl 1():S63-9. PubMed ID: 9888645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats.
    Proctor SD; Pabla CK; Mamo JC
    Atherosclerosis; 2000 Apr; 149(2):315-22. PubMed ID: 10729381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triglycerides and atherogenic lipoproteins: rationale for lipid management.
    Krauss RM
    Am J Med; 1998 Jul; 105(1A):58S-62S. PubMed ID: 9707269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.